Цель исследования -оценка эффективности и безопасности фавипиравира для лечения новой коронавирусной инфекции (COVID-19) легкого и среднетяжелого течения.Материал и методы. Проведено открытое рандомизированное многоцентровое клиническое исследование с активным контролем у амбулаторных и госпитализированных пациентов с COVID-19 легкого и сред-

A dangerous viral disease COVID-19, caused by a new RNA coronavirus SARS-COV-2, has been actively spreading in the world since December 2019. The main manifestations of this disease are bilateral pneumonia, often accompanied by the development of acute respiratory syndrome and respiratory failure. Patients with diabetes mellitus (DM) are at high risk of infection with the SARS-COV-2 virus, severe illness and death.Maintaining of target glycemic levels is the most important factor in a favorable outcome of COVID-19 in both type 1 and type 2 DM. The choice of antihyperglycemic therapy in a patient with DM in the acute period of COVID-19 depends on the initial therapy, the severity of hyperglycemia, the severity of the viral infection and the patient’s clinical condition.The article presents the recommendations of the board of experts of the Russian Association of Endocrinologists on glycemic control and the choice of antihyperglycemic therapy in patients with type 2 DM and COVID-19, and also on the use of glucocorticosteroids used in the treatment of COVID-19 in patients with type 2 DM.

No abstract

Objective of the Review: To systematise the information on the incidence of diabetes mellitus (DM) in patients who had the novel coronavirus infection; on the features of virus mechanism activation and pathological cascades in the body; on potential ways to control blood glucose during COVID-19. Key Points. During the novel coronavirus pandemic (COVID-19) associated with high death toll in all countries, specific groups of patients were identified, where the death rate was higher than the mean figures. These groups include DM patients. DM is associated with a high risk of severe coronavirus infection and is the second common comorbidity during COVID-19. DM, degree of its compensation and complications progression impact prognosis, coronavirus infection clinical course and survival. Therefore, effective teamwork of the healthcare professionals and patient is essential. The primary objective of coordination is creation of a clear algorithm of DM management during COVID-19: strict blood glucose monitoring and prompt intensification both of antihyperglycemic therapy and specific ethiopathogenetic management of COVID-19. Conclusion. DM patients require special attention and timely adequate assistance both in outpatient and inpatient settings. Long-term follow-up of DM patients after COVID-19 to minimise the risk of DM complications is also very important. Keywords: COVID-19, diabetes mellitus, novel coronavirus infection.